Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,177
archived clinical trials in
Orthopedic

Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab
Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation
Status: Enrolling
Updated:  12/31/1969
William Beaumont Army Medical Center
mi
from
Fort Bliss, TX
Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab
Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation
Status: Enrolling
Updated: 12/31/1969
William Beaumont Army Medical Center
mi
from
Fort Bliss, TX
Click here to add this to my saved trials
Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab
Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation
Status: Enrolling
Updated:  12/31/1969
Brooke Army Medical Center
mi
from
San Antonio, TX
Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab
Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation
Status: Enrolling
Updated: 12/31/1969
Brooke Army Medical Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab
Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation
Status: Enrolling
Updated:  12/31/1969
Madigan Army Medical Center
mi
from
Tacoma, WA
Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab
Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation
Status: Enrolling
Updated: 12/31/1969
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Bone Density in Voluntary Apheresis Blood Donors
Randomized Longitudinal Study of Apheresis Voluntary Blood Donors' Bone Density
Status: Enrolling
Updated:  12/31/1969
BloodCenter of Wisconsin
mi
from
Milwaukee, WI
Bone Density in Voluntary Apheresis Blood Donors
Randomized Longitudinal Study of Apheresis Voluntary Blood Donors' Bone Density
Status: Enrolling
Updated: 12/31/1969
BloodCenter of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Shared Decision Making in Older Adults With Distal Radius Fractures
Shared Decision Making in Older Adults With Distal Radius Fractures
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Shared Decision Making in Older Adults With Distal Radius Fractures
Shared Decision Making in Older Adults With Distal Radius Fractures
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
TriWest Research Assocaites
mi
from
El Cajon, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
TriWest Research Assocaites
mi
from
El Cajon, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Inlande Rheumatology Clinical Trials
mi
from
Upland, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Inlande Rheumatology Clinical Trials
mi
from
Upland, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
mi
from
Colorado Springs, CO
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of CT/NY
mi
from
Danbury, CT
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of CT/NY
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Sarasota Arthritis Center
mi
from
Sarasota, FL
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Sarasota Arthritis Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
West Broward Rheumatology Associates, Inc.
mi
from
Tamarac, FL
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
West Broward Rheumatology Associates, Inc.
mi
from
Tamarac, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Institute of Arthritis Research
mi
from
Idaho Falls, ID
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Institute of Arthritis Research
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis and Diabetes Clinic, Inc
mi
from
Monroe, LA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis and Diabetes Clinic, Inc
mi
from
Monroe, LA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Osteoporosis And Clinical Trial Center
mi
from
Cumberland, MD
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Osteoporosis And Clinical Trial Center
mi
from
Cumberland, MD
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Osteoporosis And Clinical Trial Center
mi
from
Hagerstown, MD
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Osteoporosis And Clinical Trial Center
mi
from
Hagerstown, MD
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Physician Research Collaboration
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Shanahan Rheumatology and Immunotherapy, PLLC
mi
from
Raleigh, NC
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Shanahan Rheumatology and Immunotherapy, PLLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Carolina Arthritis Associates
mi
from
Wilmington, NC
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Carolina Arthritis Associates
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Seattle Rheumatology Associates
mi
from
Seattle, WA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Seattle Rheumatology Associates
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Arthritis Northwest Rheumatology
mi
from
Spokane, WA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Arthritis Northwest Rheumatology
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Investigational Site Number 032001
mi
from
Capital Federal,
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Investigational Site Number 032001
mi
from
Capital Federal,
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Glacier View Research Institute
mi
from
Kalispell, MT
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Glacier View Research Institute
mi
from
Kalispell, MT
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Care Access Research - Huntington Beach
mi
from
Huntington Beach, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Care Access Research - Huntington Beach
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Rheumatology Center of San Diego
mi
from
Escondido, CA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Rheumatology Center of San Diego
mi
from
Escondido, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Marietta Rheumatology
mi
from
Marietta, GA
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Marietta Rheumatology
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
mi
from
Columbia, SC
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Articularis Healthcare Group, INC dba Columbia Arthritis Ctr
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Physicians at Brooklyn Heights
mi
from
Brooklyn, NY
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Physicians at Brooklyn Heights
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Motor-Sparing Peripheral Nerve Blockade Facilitates Mobility Post Total Knee Arthroplasty: A Randomized Controlled Trial
Randomized Comparative Effectiveness Trial of Anesthesia/Analgesia Techniques for Primary Total Knee Arthroplasty
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Motor-Sparing Peripheral Nerve Blockade Facilitates Mobility Post Total Knee Arthroplasty: A Randomized Controlled Trial
Randomized Comparative Effectiveness Trial of Anesthesia/Analgesia Techniques for Primary Total Knee Arthroplasty
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Valley Perinatal
mi
from
Scottsdale, AZ
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Valley Perinatal
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Heinen Obstectrics & Gynecology
mi
from
Eunice, LA
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Heinen Obstectrics & Gynecology
mi
from
Eunice, LA
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Newlife Wellness OBGYN
mi
from
Brooklyn, NY
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Newlife Wellness OBGYN
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Lakeshore Women's Specialists
mi
from
Mooresville, NC
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Lakeshore Women's Specialists
mi
from
Mooresville, NC
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Cincinnati Obgyn
mi
from
Cincinnati, OH
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Cincinnati Obgyn
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
James D. Kasten, M.D., Inc.
mi
from
Norwalk, OH
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
James D. Kasten, M.D., Inc.
mi
from
Norwalk, OH
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Regional Obstetrical Consultants
mi
from
Chattanooga, TN
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Regional Obstetrical Consultants
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated:  12/31/1969
Texas Maternal-Fetal Medicine
mi
from
Webster, TX
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women
Status: Enrolling
Updated: 12/31/1969
Texas Maternal-Fetal Medicine
mi
from
Webster, TX
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of California Davis
mi
from
Davis, CA
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of California Davis
mi
from
Davis, CA
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Royal Children's Hospital
mi
from
Melbourne,
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Royal Children's Hospital
mi
from
Melbourne,
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of California Davis
mi
from
Davis, CA
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of California Davis
mi
from
Davis, CA
Click here to add this to my saved trials
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials